Pricing Log in Create free account
Friday 6 November 2026 Export OSUR’s income statement to Excel — free account

OraSure Technologies, Inc.

OSUR Healthcare Medical Instruments & Supplies

OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024.

Revenue
−1.93%
EPS
+134.6%
Free cash flow
−1.40%
Total debt
−8.27%

Quarter to June 2026, against a year earlier

3.49 0.12 +3.56%
Market cap
$232.4M
P/E
0.0×
Fwd P/E
−6.5×
Dividend yield
—
F-score
3/9
Altman Z
1.47
Beneish M
−2.73
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.55
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 4 — 1 — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 6.66%

Capital & Financial Ratios $m

Size
Market Cap 232.42
Revenue ttm 112.41
Net income ttm (49.13)
Free cash flow ttm (48.83)
Net debt Q (160.46)
Valuation
P/E 0.00
Forward P/E (6.51) (negative: loss-making)
Price / sales 2.07
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.73
Financial health
Current ratio Q 8.88 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 17.58
Growth
Revenue growth Q −1.93% (below 0%: shrinking)
Operating income growth Q +130.18% (above 0%: growing)
EPS, this year +35.64% (at or above 15%: strong)
EPS, next year A −2.48% (below 0%: weak)
Revenue, next year A +5.46%
EPS, past 5 yrs —
EPS, next 5 yrs A +21.77% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.6×, against a ten-year median of 2.1×; over the ten years it ranged from −0.3× in 2025 to 8.2× in 2017.
P/S against its own 10 years 38.25%
10-year low 10-year high
P/B against its own 10 years 17.27%
10-year low 10-year high
EV/Sales against its own 10 years 23.85%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 290 268 199 161
Receivables 40 24 22 27
Inventory 48 34 31 30
Other 2 3 4 2
386 333 262 223
2023 2024 2025 Q'26
Payables 13 8 7 8
ST’ Debt — — — —
Other 25 22 18 16
40 33 40 25

Compound Annual Growth %

10y 5y 3y
Sales (0.40%) (7.70%) (33.29%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 7.89% (3.08%) (2.21%)

Earnings Trends EPS, adjusted, against the consensus

Q4 FY25 Estimate −0.17 Actual −0.19

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY25 −0.15 −0.18 Miss by 0.03
Q2 FY25 −0.15 −0.19 Miss by 0.04
Q3 FY25 −0.16 −0.13 Beat by 0.03
Q4 FY25 −0.17 −0.19 Miss by 0.02
Q3 FY26 −0.18 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.32) 0.09 — — —
’25 (0.21) (0.26) (0.19) (0.27) (0.94)
’24 (0.05) (0.01) (0.06) (0.14) (0.26)
’23 0.37 (0.07) 0.15 0.27 0.72
’22 (0.28) (0.26) 0.07 0.21 (0.25)
’21 0.05 (0.02) (0.21) (0.14) (0.32)
’20 (0.12) (0.16) 0.01 0.03 (0.22)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 28 31 — — —
’25 30 31 27 27 115
’24 54 54 40 37 186
’23 155 85 89 76 405
’22 68 80 116 123 387
’21 59 58 54 64 234
’20 32 29 48 63 172
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (14) (10) — — —
’25 (20) (10) (10) (9) (49)
’24 7 8 13 0 27
’23 6 57 37 41 142
’22 (36) (10) 16 (18) (47)
’21 (4) 1 (19) (13) (35)
’20 2 (5) 4 4 6
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (12) — — —
’25 (19) (12) (11) (11) (53)
’24 5 6 13 0 24
’23 5 52 35 40 131
’22 (84) (21) 9 (15) (111)
’21 (15) (11) (24) (33) (83)
’20 0 (8) (1) (12) (23)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 128 167 182 155 172 234 387 405 186 115 112 (1.2%) 121 131 141 +6.9%
Gross margin, % 68.66 59.23 62.51 61.18 59.32 50.33 38.31 42.33 42.72 41.90 42.58 (26.8) pt
EBT 20 41 32 21 (4) (9) (16) 56 (16) (65) (47) n/m
EBT margin, % 15.85 24.56 17.45 13.80 (2.05) (3.98) (4.05) 13.87 (8.61) (56.15) (41.48) (72.0) pt
Net income 20 31 20 17 (15) (23) (17) 54 (19) (69) (49) n/m
Per share, $
Per share, $ Revenue 2.31 2.83 2.97 2.51 2.54 3.25 5.34 5.53 2.50 1.57 1.63 (4.2%)
Earnings 0.35 0.52 0.33 0.27 (0.22) (0.32) (0.25) 0.73 (0.26) (0.94) (0.69) n/m
Cash flow 0.44 0.48 0.64 0.16 0.09 (0.49) (0.65) 1.93 0.37 (0.67) (0.62) n/m
Capex (0.08) (0.07) (0.10) (0.15) (0.43) (0.67) (0.88) (0.14) (0.05) (0.06) (0.09) (3.4%)
Free cash flow 0.36 0.40 0.54 0.01 (0.34) (1.16) (1.53) 1.79 0.32 (0.72) (0.71) n/m
Book value 3.34 4.37 4.64 4.98 5.90 5.29 5.03 5.87 5.51 4.64 4.61 +3.7%
Shares, m 56 59 61 62 68 72 73 73 74 73 71 +3.1%
Valuation, ×
Valuation, × P/E 25.11 36.40 34.35 29.74 0.00 0.00 0.00 11.50 0.00 0.00 0.00 13.7
P/S 3.81 6.82 3.93 3.20 4.16 2.68 0.90 1.50 1.45 1.55 2.07 3.0
P/B 2.63 4.41 2.52 1.61 1.79 1.64 0.95 1.41 0.65 0.52 0.73 1.8
EV/Sales 2.87 5.89 3.07 2.20 2.95 2.03 0.61 0.78 0.01 (0.19) 0.65 2.0
EV/FCF 18.17 41.28 17.02 694.46 (24.27) (5.68) (2.13) 2.42 0.04 0.40 (1.49) 74.2
Cash, $m
Cash, $m Operating cash flow 25 28 39 10 6 (35) (47) 142 27 (49) (43) n/m
Capex (4) (4) (6) (9) (29) (48) (64) (10) (4) (4) (6) (0.4%)
Free cash flow 20 24 33 0 (23) (83) (111) 131 24 (53) (49) n/m
Balance, $m
Balance, $m Working capital 139 190 191 192 242 231 256 347 300 222 198 +5.3%
Net debt (121) (156) (157) (155) (209) (151) (110) (290) (268) (199) (160) +5.7%
Shareholders’ equity 186 258 283 307 399 381 364 431 410 341 318 +7.0%
Returns, %
Returns, % ROA 9.93 12.28 6.67 5.01 (3.71) (5.02) (3.79) 11.58 (4.05) (15.57) (12.20) (25.5) pt
ROIC 19.52 24.61 14.01 7.64 (1.70) (2.77) (5.45) 14.54 (12.37) (31.75) (21.46) (51.3) pt
ROE 11.42 13.94 7.53 5.64 (4.23) (5.90) (4.60) 13.50 (4.64) (18.30) (14.07) (29.7) pt
People
People Employees 325 377 398 472 570 785 840 638 501 500 — +4.9%
Revenue/emp, $m 0.39 0.44 0.46 0.33 0.30 0.30 0.46 0.64 0.37 0.23 — (5.8%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

OraSure Technologies, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NNNN Anbio Biotechnology $516.6M — — — — — — — Compare
ZJYL Jin Medical International Ltd. $509.4M — — — — −8,074.17% (below 0%: shrinking) 34.44% 0.00% Compare
ANGO AngioDynamics, Inc. $496.7M — (loss-making) — (loss-making) +6.87% (above 0%: growing) n/m +5.62% (above 0%: growing) 59.37% (9.02%) Compare
EMBC Embecta Corp. $358.7M 4.2× 5.3× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92% Compare
SMTI Sanara MedTech Inc. $290.4M — (loss-making) 164× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33% Compare
OSUR OraSure Technologies, Inc. $232.4M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76%
UTMD Utah Medical Products, Inc. $202.4M 21.7× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06% Compare
PDEX Pro-Dex, Inc. $195.8M 16.4× 18.8× +10.96% (above 0%: growing) −33.57% (below 0%: shrinking) +177.76% (above 0%: growing) 33.35% 17.10% Compare
KRMD KORU Medical Systems, Inc. $139.9M — (loss-making) — (loss-making) +18.15% (above 0%: growing) n/m +26.17% (above 0%: growing) 65.14% 5.21% Compare
Median of peers $324.5M 16.4× 23.8× +7.96% −33.57% +5.62% 56.42% 6.33%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Directors and executive officers, together 4.70%
Private Management Group Inc15635 Alton Parkway, Suite 7.60%
BlackRock, Inc.55 East 7.50%
The Vanguard Group100 Vanguard Blvd.Malvern, PA 6.10%
Neuberger Berman Group LLC 5.90%
Neil Gagnon 5.20%
Dimensional Fund Advisors LP 5.10%
Altai Capital Management, L.P. PO Box 5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

OraSure Technologies, Inc. (OSUR) Latest News

26 Oct

Impact 3 · · GlobeNewswire

6 Sep

Impact 3 ·

12 Aug

Impact 3 · · The Motley Fool transcript

6 Aug

Impact 3 · · Moby transcript
Impact 3 · transcript
Impact 3 · · MarketBeat

5 Aug

Impact 3 ·

21 Jul

Impact 4 ·

11 Jun

Impact 4 ·

7 May

Impact 3 · · Moby

6 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · GlobeNewswire
Impact 3 · · MarketBeat

16 Apr

Impact 4 · · Insider Monkey

17 Mar

Impact 4 · · GlobeNewswire
Impact 4 · · Business Wire

26 Feb

Impact 4 · · Moby
Impact 4 · · MarketBeat
Impact 4 · · GuruFocus.com

25 Feb

Impact 4 · · Associated Press Finance
Impact 4 ·

10 Feb

Impact 4 · · GlobeNewswire

15 Jan

Impact 3 · · GlobeNewswireSimply Wall St.MT NewswiresSimply Wall St.
Impact 3 · · Business WireSimply Wall St.MT NewswiresSimply Wall St.MT NewswiresMT NewswiresMT NewswiresBenzinga

6 Jan

Impact 4 · · Zacks

5 Jan

Impact 4 · · GlobeNewswire

17 Dec

Impact 3 · · GlobeNewswire
Impact 3 · · Business Wire

16 Nov

Impact 3 · · Simply Wall St.

6 Nov

Impact 3 · · GuruFocus.com transcript
stockrow.com/OSUR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com